Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co.'s Solid Growth Turbo-Charged By Lagevrio For COVID-19

Executive Summary

Even without Lagevrio, Merck's base business grew by double digits; the company raised its revenue guidance for the year.

You may also be interested in...



Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication

The CheckMate-901 trial failed on one of its primary endpoints, but the company will continue the trial to explore additional primary endpoints.

ICER Gives Cold Shoulder To Merck/Ridgeback’s COVID-19 Pill

Group’s final report said evidence was inadequate to demonstrate a net health benefit versus symptomatic care for Lagevrio, a drug that has already taken a back seat to Pfizer’s Paxlovid.

BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long

The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel